20xx中國國際醫(yī)藥高峰論壇上的演講(ppt30中英文)-演講技能-閱讀頁
2024-09-06 11:40本頁面
【正文】 anies 研發(fā)通常在醫(yī)藥公司外部開展 ? Low or very low industry investment in Ramp。D for pharmaceutical panies 沒有形成全面的激勵體制來鼓勵醫(yī)藥公司的研發(fā) Building a strong Chinese Ramp。D研發(fā)投資低 ? limited development and marketing skills 有限的開發(fā)和營銷技巧 ? lack of focused product portfolio 缺乏有針對性的產(chǎn)品組合 ? low profitability 利潤低 ? consolidation, streamlining and focus 合并集中 ? license in from abroad 國外授權 ? alliance with local startups and universities 與國內企業(yè)和大學聯(lián)合 Current目前 ? Build and manage a strong Ramp。D有足夠資 金進行研發(fā) ? international standard (GMP)國際標準 Future將來 Opportunities: Upgrade to international standards 提高到國際水平 ? Focus their product portfolio on specific therapeutic areas 將產(chǎn)品集中在特定治療領域 ? Establish a long term planning (lifecycle planning) for their products 為產(chǎn)品進行長期計劃（生命周期計劃） ? Build step by step a prehensive research program (short/mid/long term) 逐步建立綜合的研究計劃（短 /中 /長期） ? Inlicense/cooperate with local and international partners 與當?shù)睾蛧H伙伴合作 ? Build up strong clinical development and marketing skills 掌握有效的臨床開發(fā)和營銷技巧 What local panies will do 當?shù)毓疽鍪裁矗? International Industry 國際醫(yī)藥行業(yè) ? China being outsourcing center for drug development and manufacturing 中國正在成為藥物開發(fā)和生產(chǎn)的外包中心 ? Preclinical costs in China are, on average, 20% of the US 中國的臨床前成本平均為美國的 20% ? Big pharmas are rapidly increasing outsourcing to China 大型醫(yī)藥公司在中國的外包業(yè)務快速增長 ? China’s domestic market being significant 中國國內市場日趨重要 ? Healthcare system privatized。D investment研發(fā)投資 ? Advanced technology: significant investment (NIH $28 billion in 2020) 先進技術：重要的投資 ? Needs lowcost drug development solutions 需要進行低成本藥物開發(fā) ? Largest markets 廣闊的市場 ? FDA pliant 適應 FDA ? Strong petition 激烈的競爭 Developed Pharma Market發(fā)達醫(yī)藥市場 ? Needs advanced technology: “l(fā)ate starter” 后來者：需要先進的技 術 ? Low drug development cost 低廉藥物開發(fā)成本 ? Current market small 市 場目前狹小 ? Generally not yet FDA pliant 基本不適應 FDA ? High market growth 市 場增長快 China中國 Opportunities: Integrate China into global market 將中國融入全球市場 ? More clinical development in China 在中國進行更多的臨床領域開發(fā) ? Ramp。D centers, cooperation and outsourcing 在中國擁有研發(fā)中心，公司和外包業(yè)務 ? Adapt their research portfolio to China’s need 根據(jù)中國需要對研究領域分配進行調整 ? Integrate China into their global Ramp。D cost and increase productivity 全球醫(yī)藥行業(yè)需要降低研發(fā)成本提高生產(chǎn)力 ? Chinese industry needs new products and clinical development and marketing expertise 中國醫(yī)藥行業(yè)需要新產(chǎn)品和臨床開發(fā)與營銷的專業(yè)技術 ? Strong life science Ramp。D investment 形成綜合激勵體系來鼓勵研發(fā)投資
試題試卷相關推薦
鄂ICP備17016276號-1